![]() ![]() The news came following an exclusive story in The Pharmaceutical Journal, which revealed that shortages are being “exacerbated” by some patients being given prescriptions for a 12-month supply.Īs part of the government’s response to HRT shortages, the health secretary appointed Madelaine McTernan, former director general of the COVID-19 vaccine taskforce, as ‘HRT tsar’ in April, with the promise of leaving “no stone unturned in our national mission to boost supply of HRT”.Īlthough HRT was perhaps the most widely reported medicines shortage in 2022, it was by no means the only one. Pharmacists were given powers to limit dispensing of some types of HRT to three months to try to improve shortages. With issues having rumbled along for more than three years, HRT shortages hit the headlines. ![]() Avery’s focus is to ensure prescribing reflects the needs of the diverse population in England, improves health outcomes and protects the environment. In March, NHS England appointed Tony Avery, a GP based in Nottingham, as its first national clinical director for prescribing. However, data revealed that the number of pharmacies in England is at its lowest level since 2015/2016 because of financial pressures on the sector.Īndrew Lane, chair of the National Pharmacy Association, said that no comfort can be taken from the figures, since the trajectory is still downwards, and there will be more closures to come without a fresh injection of funds. These negotiations led to the introduction of a national contraception management service and the expansion of the NHS Community Pharmacist Consultation Service to include referrals from emergency care, but the shelving of plans for an English version of ‘Pharmacy First’.Īn analysis by The Pharmaceutical Journal revealed that pharmacy closures have slowed significantly, halving in 2021 compared with 2020. ![]() In February, the Pharmaceutical Services Negotiating Committee appointed Janet Morrison as its new chief executive, who went on to negotiate the final two years of the community pharmacy contract in England. ![]() The new guidance came on the back of a plethora of cardiovascular outcome trial data in recent years and meant that people with type 2 diabetes mellitus, who also have cardiovascular disease or are at high risk of developing it, were offered a SGLT2 inhibitor in addition to metformin earlier in their treatment. The National Institute for Health and Care Excellence recommended a change in treatment for patients with type 2 diabetes mellitus. Guidance that would impact one of the largest patient groups in the UK was published. But the limited supply, short treatment window and small number of patient groups eligible to receive antivirals gave rise to concerns about whether they could really turn the tide on the pandemic.īy the end of the year, draft guidance from the National Institute for Health and Care Excellence recommended Paxlovid but not molnupiravir or remdesivir as options for treating COVID-19 in adults on the grounds that they were not cost-effective. Paxlovid became the first-line treatment choice, followed by remdesivir, with molnupiravir pushed down to a third-line option. Journal of Pharmaceutical Health Services ResearchĢ022 kicked off on a positive note as new antiviral Paxlovid (nirmatrelvir and ritonavir Pfizer) was recommended for patients with COVID-19.International Journal of Pharmacy Practice.Antimicrobial resistance and stewardship. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |